How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,105 results for

Alcoholic Hepatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring. Full Text available with Trip Pro

Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring. Little is known regarding the risk of hepatic steatosis (HS) among adult children of affected parents. We examined the association between parental and offspring HS in the multigenerational Framingham Heart Study, which characterized HS using computed tomography.We performed multivariable logistic regression models adjusted for age, sex, alcohol use, and body mass index to generate (...) the odds of HS according to parental HS. We determined the proportion of participants with HS according to parental HS and the presence or absence of hypertension, diabetes, or obesity (BMI ≥30 kg/m2 ). After excluding heavy alcohol use (n = 126) and missing covariates (n = 1), 785 offspring with at least one parent were included.Approximately 23% (183/785) had at least one parent with HS and 1.1% had two affected parents (9/785). In adjusted models, participants with at least one parent with HS had

2018 Liver International

142. Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths. (Abstract)

Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths. Understanding the role of modest alcohol consumption in patients with non-alcohol induced fatty liver disease (NAFLD) remains a significant challenge, with no clear guidance on counselling regarding alcohol use. Conventionally, the strong association of alcohol excess and development of complications related to chronic liver disease, including hepatocellular carcinoma, has led (...) practitioners to advocate complete abstinence to those with NAFLD. New evidence published in this issue of the Red Journal challenges the historic paradigm by showing that modest, non-binge wine consumption (<70 g/week) associates with significantly lower risk of advanced hepatic fibrosis on biopsy compared with complete abstinence across a well-characterised single centre cohort of nearly 200 patients with NAFLD.

2018 American Journal of Gastroenterology

143. Effects of DA-5513 on alcohol metabolism and alcoholic fatty liver in rats Full Text available with Trip Pro

Effects of DA-5513 on alcohol metabolism and alcoholic fatty liver in rats Hangover is characterized by a number of unpleasant physical and mental symptoms that occur after heavy alcohol drinking. In addition, consistently excessive alcohol intake is considered as a major reason causes liver disease. The present study investigated the in vivo effects of DA-5513 (Morning care® Kang Hwang) on biological parameters relevant to hangover relief and alcoholic fatty liver. Blood alcohol (...) in the groups treated with DA-5513 or Yeomyung®, as compared with control rats. However, Ukon® did not produce any significant effects on these parameters. Treatment with DA-5513 significantly reduced serum aspartate and alanine aminotransferase activities and markedly reduced serum cholesterol and triglyceride levels, as compared with control rats. Histological observations using Oil Red O staining found that DA-5513 delayed the development of alcoholic fatty liver by reversing hepatic fat accumulation

2018 Laboratory animal research

144. FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest Full Text available with Trip Pro

responses, and problems. Finally, we characterized the effect of recombinant human FGF21 injection on ad libitum alcohol intake in mice.We show that alcohol ingestion (25.3 g or ∼2.5 standard drinks) acutely increases plasma levels of FGF21 (1-181) 3.4-fold in fasting humans. We also find that binge drinking for three days at Oktoberfest is associated with a 2.1-fold increase in baseline FGF21 (1-181) levels, in contrast to minor deteriorations in metabolic and hepatic biomarkers. However, basal FGF21 (...) (1-181) levels were not correlated with differences in alcohol-related behaviors, emotional responses, or problems in our non-alcoholic subjects. Finally, we show that once-daily injection of recombinant human FGF21 reduces ad libitum alcohol intake by 21% in mice.FGF21 (1-181) is markedly increased in circulation by both acute and sub-chronic alcohol intake in humans, and reduces alcohol intake in mice. These observations are consistent with a role for FGF21 as an endocrine inhibitor of alcohol

2018 Molecular metabolism

145. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD) Full Text available with Trip Pro

causes of chronic liver disease (alcohol consumption <20 gr/day, hepatitis B surface-antigen negative, anti-hepatitis C virus antibody negative, transferrin saturation <50%). Significant hepatic fibrosis was estimated by high NFS (>0.676) and calculated with previously published formula. Subjects with NAFLD and high NFS have significant NASF.NHANES III included 20 050 adult participants. 2515 participants complete data and NAFLD with 5.1% (n=129) meeting criteria for significant SF. Subjects (...) Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD) Hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) independently predicts mortality. Given liver biopsy's invasive nature, non-invasive method to assess hepatic steatosis and fibrosis provides NAFLD risk stratification algorithm in clinical practice. NAFLD fibrosis score (NFS) is simple and non-invasive predictive model recommended

2018 BMJ open gastroenterology

146. Effect of alcohol consumption on survival in non-alcoholic fatty liver disease: a national prospective cohort study. Full Text available with Trip Pro

of their survival. We diagnosed NAFLD based on a previously validated biochemical model (Hepatic Steatosis Index). We built multivariate Cox proportional hazards models to evaluate the effect of alcohol consumption on survival of patients with NAFLD. After excluding participants with significant alcohol use, viral hepatitis, or increased transferrin saturation, 4,568 participants with NAFLD were included in the analysis. In a Cox model adjusted for age, sex, and smoking history, drinking 0.5-1.5 drinks per day (...) Effect of alcohol consumption on survival in non-alcoholic fatty liver disease: a national prospective cohort study. Nonalcoholic fatty liver disease (NAFLD) comprises more than two thirds of patients with chronic liver disease in the United States. The effect of alcohol consumption on survival in patients with NAFLD is not clear. We gathered data on National Health and Nutrition Examination Survey participants from 1988 to 2010, and linked them to the National Death Index for follow-up

2018 Hepatology

147. Alcohol Biosensor Monitoring for Alcoholic Liver Disease

: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Information provided by (Responsible Party): Andrea DiMartini, University of Pittsburgh Study Details Study Description Go to Brief Summary: Successful treatment of alcohol associated liver disease (AALD) depends primarily on abstinence from alcohol. The investigators propose a randomized clinical trial of alcohol biosensor monitoring for patients with alcohol associated liver disease to determine if monitoring with feedback on alcohol use (...) Inclusion Criteria: Patients with AALD followed at our liver disease clinic, 18 years or older, willing to accept randomization, and agree to wear device for 3 months, SOCRATES problem recognition subscale score >26 (scores <26 indicate very low recognition of an alcohol problem). Exclusion Criteria: Non-English speaking, Montreal Cognitive Assessment (MOCA) scores <21 (moderate cognitive impairment) or neurologic diseases (e.g. Parkinson's), patients with unresponsive acute alcoholic hepatitis, multi

2018 Clinical Trials

148. Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. (Abstract)

Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. Alcoholic hepatitis is characterised by florid hepatic inflammation, liver failure, and death within 28 days in 35% of patients. We recently showed proliferative peripheral blood mononuclear cell (PBMC) responses to alcohol dehydrogenase (ADH) in patients with alcohol-related cirrhosis, associated with T-helper-type 1 (Th1) immunity and disease severity. We aimed to define whether ADH-specific cellular (...) immunity is present in alcoholic hepatitis.PBMCs were collected from 15 patients with alcoholic hepatitis (modified Maddrey's discriminant function >32), nine with alcohol-related cirrhosis (long-term alcohol abstinence), and three healthy controls. 25 overlapping peptides, spanning the human ADH β1 subunit, were constructed. Proliferation to ADH peptides (1 × 10(5) cells per well, cultured with 10 mM peptides for 7 days) was assessed by (3)H-thymidine incorporation. A stimulation index (SI) of 2·5

2015 Lancet

149. Non-alcoholic fatty liver disease (NAFLD): When should I suspect NAFLD?

a person has NAFLD if they have: suggestive of the metabolic syndrome or other risk factors for NAFLD. Persistent elevation of LFTs for 3 months or more — typically alanine aminotransferase (ALT) levels are raised up to 3 times the upper limit of normal, and exceed aspartate aminotransferase (AST) levels. Upper abdominal ultrasound scan findings consistent with fatty liver changes (increased hepatic echogenicity). Do not use routine liver blood tests to rule out NAFLD — be aware that LFTs and liver (...) Non-alcoholic fatty liver disease (NAFLD): When should I suspect NAFLD? Diagnosis | Diagnosis | Non-alcoholic fatty liver disease (NAFLD) | CKS | NICE Search CKS… Menu Diagnosis Non-alcoholic fatty liver disease (NAFLD): When should I suspect NAFLD? Last revised in October 2016 When should I suspect NAFLD? In most people, non-alcoholic fatty liver disease (NAFLD) is detected incidentally when liver function tests (LFTs) or abdominal ultrasound scan are performed for some other reason. Suspect

2017 NICE Clinical Knowledge Summaries

150. Non-alcoholic fatty liver disease (NAFLD): How should I assess a person with NAFLD?

hepatitis may increase the risk of progression of NAFLD [ ] and can increase the severity of liver fibrosis [ ; ]. In addition, NAFLD can exacerbate liver damage in chronic hepatitis C, haemochromatosis, and alcoholic liver disease [ ; ; ]. The information that low titres of auto-antibodies may be an incidental finding in people with NAFLD is based on expert opinion in a review article [ ]. The EASL clinical practice guidelines recommend that all people with a fatty liver should be screened for features (...) of the metabolic syndrome. The risk of impaired glucose regulation and type 2 diabetes is closely associated with the severity of NAFLD [ ], and poor blood glucose control increases the risk of fibrosis in people with non-alcoholic steatohepatitis (NASH) [ ]. The recommendation to check renal function tests is based on the fact that people with NAFLD are more at risk of developing chronic kidney disease (CKD) [ ], and CKD can be found in 20–50% of people with NAFLD [ ]. The information on alpha-1-antitrypsin

2017 NICE Clinical Knowledge Summaries

151. Finding Quality Addiction Care in Canada: Drug and Alcohol Treatment Guide

and other harms by providing a safe, supervised environment for drug use. Managed alcohol programs provide shelter and carefully dosed amounts of alcohol to people who are homeless and have chronic alcohol use problems. Through close monitoring in a safe environment, these shelters allow their residents to avoid the withdrawal symptoms associated with alcohol dependence. Overdose prevention and response provides training and naloxone kits for people who are at risk of overdosing on opioids and those who (...) and treatment settings. The best fit for you will depend on many things, including how severe your problem is and your physical and mental health. These details are determined through a comprehensive assessment by a qualified addiction or healthcare provider. Outpatient (community): Delivered in a variety of places in the community, such as an addiction or healthcare provider’s office, a mental health clinic or an addiction clinic. Most often used by people whose alcohol or other drug use does not put them

2017 Canadian Centre on Substance Abuse

152. Pharmacological Treatment of Patients with Alcohol Use Disorder

for indications other than AUD. It also does not address the manage- ment of individuals who are intoxicated with alcohol, who require pharmacotherapy for the acute treatment of alcohol withdrawal, or who are experiencing other acute medical problems related to alcohol use. Evidence-based psychotherapeutic treatments for AUD, including cognitive-behavioral therapy (CBT), twelve-step facilitation (TSF), and motivational enhancement therapy (MET) (Anton et al. 2006; Martin and Rehm 2012; Project MATCH Research (...) Pharmacological Treatment of Patients with Alcohol Use Disorder THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE Pharmacological Treatment of Patients With Alcohol Use Disorder THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH ALCOHOL USE DISORDER WWW.APPI.ORG A lcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1

2017 American Psychiatric Association

153. Frequent Emergency Department Visits are More Prevalent in Psychiatric, Alcohol Abuse, and Dual Diagnosis Conditions than in Chronic Viral Illnesses Such as Hepatitis and Human Immunodeficiency Virus. (Abstract)

Frequent Emergency Department Visits are More Prevalent in Psychiatric, Alcohol Abuse, and Dual Diagnosis Conditions than in Chronic Viral Illnesses Such as Hepatitis and Human Immunodeficiency Virus. Repeat users of Emergency Departments (ED), so-called "frequent visitors," place a substantial burden on limited ED resources. The illness features of frequent visitors have not been well defined, though chronic medical and psychiatric illness and substance abuse are implicated.This study assessed (...) whether chronic conditions such as hepatitis C (HCV) and human immunodeficiency virus (HIV) are more prevalent in frequent ED users compared to a viral condition with relatively less disability, hepatitis B (HBV). As a comparison, psychiatric complaints and alcohol abuse were also compared in frequent and non-frequent visitors.All visits to a university ED in a particular calendar year were retrospectively reviewed. Frequent visitors were defined as those who made four or more visits. Presenting

2013 Journal of Emergency Medicine

154. Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. (Abstract)

Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. Severe alcoholic hepatitis (AH) is a life-threatening condition lacking good serologic markers to tailor treatment and predict recovery. We examined the cholesterol metabolism in severe AH to explore prognostic markers and evaluate the profile of cholesterol precursors, cholestanol and phytosterols, in this context. We assessed serum cholesterol, cholesterol precursors, cholestanol, phytosterols

2018 Lipids Controlled trial quality: uncertain

155. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. Full Text available with Trip Pro

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. 29385313 2018 05 01 2018 12 02 1527-6473 24 5 2018 05 Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Liver Transpl. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. 711 10.1002 (...) /lt.25026 Sussman Norman L NL Abdominal Transplant and Liver Disease Clinic, Baylor College of Medicine, Houston, TX. Kelly James H JH Cell Machines, Inc., Houston, TX. eng Letter Comment 2018 04 06 United States Liver Transpl 100909185 1527-6465 IM Liver Transpl. 2018 Mar;24(3):380-393 29171941 Hepatitis, Alcoholic Humans Liver Transplantation Prospective Studies 2017 12 25 2018 01 29 2018 2 1 6 0 2018 5 2 6 0 2018 2 1 6 0 ppublish 29385313 10.1002/lt.25026

2018 Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Controlled trial quality: uncertain

156. The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Full Text available with Trip Pro

to compare clinical effectiveness and cost-effectiveness of integrated alcohol treatment compared to enhanced treatment as usual (TAU) on alcohol consumption and economic outcomes among patients ever infected with HCV.Patients recruited from three liver centers who had current or prior chronic HCV and qualifying alcohol screener scores were randomly assigned to enhanced TAU or the Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention. All patients received enhanced TAU, consisting of a patient (...) The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Among patients with hepatitis C virus (HCV) infection, alcohol synergistically increases the risk of cirrhosis, hepatocellular carcinoma, and death. Randomized controlled trials of integrated models of HCV-alcohol treatment have been recommended but only performed in patients with severe alcohol use disorders.This pragmatic randomized controlled trial seeks

2018 Contemporary clinical trials Controlled trial quality: uncertain

157. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Full Text available with Trip Pro

Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Alcoholic hepatitis (AH) has the most severe presentation among alcohol-related liver diseases. Corticosteroids are the most widely recommended treatment for severe AH. However, more innovative, refined treatment measures are required because of its high mortality despite corticosteroid treatment

2018 Trials Controlled trial quality: uncertain

158. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. (Abstract)

Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. 28412295 2018 12 14 2018 12 14 1600-0641 67 1 2017 07 Journal of hepatology J. Hepatol. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial. 12-14 S0168-8278(17)30210-6 10.1016/j.jhep.2017.04.001 Louvet Alexandre A Service des maladies de l'appareil digestif, Hôpital Huriez, Lille, France. Electronic address: alexandre.louvet@chru (...) -lille.fr. Peck-Radosavljevic Markus M Abteilung Gastroenterologie & Hepatologie, Endokrinologie und Nephrologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria. Electronic address: markus@peck.at. eng Editorial Comment 2017 04 13 Netherlands J Hepatol 8503886 0168-8278 IM J Hepatol. 2017 Jul;67(1):120-127 28161471 Hepatitis, Alcoholic Homozygote Humans 2017 03 14 2017 03 27 2017 04 04 2017 4 17 6 0 2018 12 15 6 0 2017 4 17 6 0 ppublish 28412295 S0168-8278(17)30210-6 10.1016/j.jhep.2017.04.001

2018 Journal of Hepatology Controlled trial quality: uncertain

159. Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. (Abstract)

Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL.We collected data from 304 patients (mean age, 52.3±12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United (...) Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection.The mean CLDQ overall score was 5.0±1.2, with the lowest score in the category fatigue (4.3±1.6) and the highest scores for activity (5.4±1.4). Women had significantly lower CLDQ scores than men (4.6±1.3 vs 5.3±1.1; P<.001). We found negative correlations between CLDQ scores and presence of obesity (P<.001), type 2 diabetes (P<.001), and dyslipidaemia (P<.01

2018 Clinical Gastroenterology and Hepatology

160. Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. (Abstract)

Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. Chronic liver diseases are characterized by the expansion of ductular reaction (DR) cells and the expression of liver progenitor cell (LPC) markers. In alcoholic hepatitis (AH), the degree of DR expansion correlates with disease progression and short-term survival. However, little is known about the biological properties of DR cells, their impact on the pathogenesis of human liver disease (...) , and their contribution to tissue repair. In this study, we have evaluated the transcriptomic profile of DR cells by laser capture microdissection in patients with AH and assessed its association with disease progression. The transcriptome analysis of cytokeratin 7-positive (KRT7+ ) DR cells uncovered intrinsic gene pathways expressed in DR and genes associated with alcoholic liver disease progression. Importantly, DR presented a proinflammatory profile with expression of neutrophil recruiting C-X-C motif chemokine

2018 Hepatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>